Investor: David Polen
Number of Assets: 6
Reporting Period: Q4 - 2025
Holdings at Report: $23,420,875,210
Return Since Report: -$367,513,293
Return Since Report: -1.57%
Company | Position | Activity | Shares | Port. % | Rep. Price | Curr. Price | Rep. Value | Curr. Value | Return Value | Return % |
|---|---|---|---|---|---|---|---|---|---|---|
| Abbott Laboratories (ABT) | Equity | -46.61% | 3,962,230 | 33.58% | $125.29 | $102.64 | $496,427,772 | $406,683,287 | -$89,744,485 | -18.08% |
| Abcellera Biologics Inc. (ABCL) | Equity | -61.93% | 102,508 | 0.02% | $3.42 | N/A | $350,577 | N/A | N/A | N/A |
| Accenture PLC (ACN) | Equity | -23.52% | 1,882,707 | 34.16% | $268.30 | $197.43 | $505,130,377 | $371,693,429 | -$133,436,948 | -26.42% |
| Acuity Inc. (AYI) | Equity | -33.81% | 1,061 | 0.03% | $360.04 | $280.15 | $382,002 | $297,239 | -$84,763 | -22.19% |
| Adaptive Biotechnologies Corp. (ADPT) | Equity | +11.87% | 325,767 | 0.36% | $16.24 | $13.72 | $5,290,456 | $4,469,523 | -$820,933 | -15.52% |
| Adobe Inc. (ADBE) | Equity | -27.55% | 1,345,588 | 31.85% | $349.99 | $243.40 | $470,942,284 | $327,516,119 | -$143,426,165 | -30.46% |